



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24
E-mail: admin@jagsonpal.com

JPL/SEC/RESU-NOT

November 13, 2010

The National Stock Exchange of India Limited
Kind Attn. Mr. Hari K. - Vice President
Exchange Plaza, Bandra-Kurla Complex
Bandra E), Mumbai - 400 051.
FAX 022-26598237-38

The Bombay Stock Exchange Limited
Pherozebhoj Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
FAX 022-22723121, 22722037, 22723719, 22722041

SUB: UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30.09.2010

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith unaudited financial results (provisional) for the quarter ended 30th September 2010.

Thanking you.

Yours faithfully,

For **JAGSONPAL PHARMACEUTICALS LIMITED**

(S.K. MATA)

COMPLIANCE OFFICER CUM COMPANY SECRETARY



Encl. : As above.



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Unaudited Financial Results for the Quarter ended 30.09.2010

Particulars		(Rs. in lacs)				
		Quarter ended 30.09.2010 Unaudited	Quarter ended 30.09.2009 Unaudited	6 Months ended 30.09.2010 Unaudited	6 Months ended 30.09.2009 Unaudited	12 Months ended 31.03.2010 Audited
1(a)	Net sales/Income from Operations	4583.54	3441.08	8700.58	6771.20	13959.34
1(b)	Other Operating Income					
	Total	4583.54	3441.08	8700.58	6771.20	13959.34
2	Expenditure					
a.	(Inc.)/Dec. in Stock in trade and work in progress	647.94	-605.44	796.49	-726.13	-1042.09
b.	Consumption of Raw Materials	1173.69	1905.46	3126.52	3480.54	7219.40
c.	Purchase of traded goods	433.40	620.79	566.71	1043.96	1372.92
d.	Employees Cost	901.38	609.04	1586.19	1125.28	2378.78
e.	Depreciation	58.09	50.05	115.11	99.83	208.50
f.	Other Expenditure	881.43	582.72	1587.60	1182.11	2458.50
g.	Total	4095.93	3162.62	7778.62	6205.59	12596.01
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	487.61	278.46	921.96	565.61	1363.33
4	Other Income	0.00	0.00	0.00	0.00	36.30
5	Profit before Int.& Exceptional Items (3+4)	487.61	278.46	921.96	565.61	1399.63
6	Interest	110.61	70.87	186.33	167.87	349.62
7	Profit After Interest but before Exceptional items (5 - 6)	377.00	207.59	735.63	397.74	1050.01
8	Exceptional Items					
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7 +8)	377.00	207.59	735.63	397.74	1050.01
10	Tax expense	100.00	40.00	135.00	80.00	125.81
11	Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	277.00	167.59	600.63	317.74	924.20
12	Extraordinary Items (net of tax expense)					
13	Net Profit (+)/ Loss (-) for the period (11-12)	277.00	167.59	600.63	317.74	924.20
14	Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
15	Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr.					6049.30
16	Earnings Per Share (EPS)					
a.	Basic & diluted EPS before extraordinary items for the period.	1.06	0.64	2.29	1.21	3.53
b.	Basic & diluted EPS after extraordinary items for the period.	1.06	0.64	2.29	1.21	3.53
17	Public shareholding :					
-	- Number of shares	8962360	8962360	8962360	8962360	8962360
-	- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%
18	Promoter and promoter group shareholding					
a.	Pledged / Encumbered					
-	- Number of shares	-	-	-	-	-
-	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
-	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
b.	Non - encumbered					
-	- Number of shares	17235640	17235640	17235640	17235640	17235640
-	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
-	- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%

Notes

- The Financial Results for the Quarter ended 30.9.2010 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 13-11-2010
- No complaints were pending at the beginning/end of the quarter ended 30.9.2010. However 36 requests for change of address/dividend revalidation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.

Place : New Delhi
Date : 13.11.2010



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Jagmohan Singh Kochhar
Chairman